Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Ilumya is a prescription interleukin-23 antagonist containing tildrakizumab-asmn. It is indicated for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Each single-dose prefilled syringe contains 100 mg in 1 mL.
read more about ilumya ...Tildrakizumab-asmn binds to the p19 subunit of interleukin-23 and blocks its interaction with the IL-23 receptor. This reduces signaling involved in release of proinflammatory cytokines and chemokines associated with plaque psoriasis.
Ilumya is used in adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Patients are evaluated for tuberculosis before treatment, and age-appropriate immunizations are considered before therapy begins.
The recommended dose is 100 mg by subcutaneous injection at week 0, week 4, and every 12 weeks thereafter. Ilumya is administered by a healthcare professional. A missed dose is administered as soon as possible, followed by return to the regular schedule.
Serious hypersensitivity reactions, including angioedema and urticaria, can occur. Ilumya can increase infection risk, and treatment is not started in patients with a clinically significant active infection until the infection resolves or is adequately treated. Live vaccines are avoided during treatment.
Ilumya treats moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
The recommended schedule is 100 mg at week 0, week 4, and every 12 weeks thereafter.
Yes. Patients are evaluated for tuberculosis infection before treatment begins.
No. Current labeling directs avoidance of live vaccines during treatment.
DailyMed - ILUMYA - tildrakizumab-asmn injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6a322bb-51b9-4f0e-8642-62a9682ffcde. Date Accessed October 2, 2026.
Five-Year Efficacy and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis Who Respond at Week 28. https://pubmed.ncbi.nlm.nih.gov/33544883/. Date Accessed October 2, 2026.
ILUMYA Prescribing Information. https://www.ilumyapro.com/content/dam/ilumya-pro/wp-content/uploads/Sun-Pharma_ILUMYA_US_Prescribing-Info-and-Medication-Guide_combined.pdf. Date Accessed October 2, 2026.
Tildrakizumab-asmn Injection - MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a618026.html. Date Accessed October 2, 2026.
Tildrakizumab Versus Placebo or Etanercept for Chronic Plaque Psoriasis - Results From Two Randomised Controlled Phase 3 Trials. https://pubmed.ncbi.nlm.nih.gov/28596043/. Date Accessed October 2, 2026.